Mizuho reiterates Establishment Labs (ESTA) as a top pick for 2026 after the company submitted its application for an FDA label expansion of the breast reconstruction indication for Motiva. Establishment also disclosed it has sold more than 60,000 Motiva implants in the U.S. since the October 2024 launch, the analyst tells investors in a research note. Mizuho sees the update as bullish for the company’s Q4 report and 2026 results.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $86 from $81 at BTIG
- Establishment Labs submits Motiva implants for FDA approval
- Establishment Labs price target raised to $85 from $72 at Canaccord
- Establishment Labs price target raised to $90 from $85 at Mizuho
- Establishment Labs Holdings: Strategic Growth and Profitability Prospects Reinforce Buy Rating